Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lun...
Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
About this item
Full title
Author / Creator
Publisher
United States: John Wiley & Sons, Inc
Journal title
Language
English
Formats
Publication information
Publisher
United States: John Wiley & Sons, Inc
Subjects
More information
Scope and Contents
Contents
Mast cells are a major component of the immune microenvironment in tumour tissues and modulate tumour progression by releasing pro‐tumorigenic and antitumorigenic molecules. Regarding the impact of mast cells on the outcomes of patients with lung adenocarcinoma (LUAD) patient, several published studies have shown contradictory results. Here, we aim...
Alternative Titles
Full title
Mast cell‐based molecular subtypes and signature associated with clinical outcome in early‐stage lung adenocarcinoma
Authors, Artists and Contributors
Author / Creator
Identifiers
Primary Identifiers
Record Identifier
TN_cdi_doaj_primary_oai_doaj_org_article_79140506a9e944ca92054b23cfb3fc11
Permalink
https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_doaj_primary_oai_doaj_org_article_79140506a9e944ca92054b23cfb3fc11
Other Identifiers
ISSN
1574-7891
E-ISSN
1878-0261
DOI
10.1002/1878-0261.12670
